Everolimus Treatment in a Series of Patients with Advanced Neuroendocrine Tumors

#765

Introduction: Everolimus is an oral mTOR inhibitor that exerts antineoplastic effects inhibiting cell proliferation, survival and angiogenesis. Its activity in advanced neuroendocrine tumors (NETs) has been demonstrated in controlled trials and everolimus was approved by the FDA for the treatment of progressive, advanced pNETs in May 2011.

Aim(s):

Materials and methods: We treated with everolimus, at the dosage of 10 mg once daily, 14 patients with advanced, progressive, low or intermediate-grade NETs for a mean period of 11 months. Somatostatin analogues treatment was continued in all patients. 12/14 patients had previously undergone Peptide Receptor Radionuclide Therapy (PRRT).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Plastino F, Iacovazzo D, Schinzari G, Barile R, Lugli F,

Keywords: everolimus, prrt,

To read the full abstract, please log into your ENETS Member account.